5 ms·
BioNTech presents positive phase 1/2 data for CAR-T cell therapy candidate
- refurb 3y ago"The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac." Not sure why this is all that interesting to HN. It's a very early trial and the outcome is "encouraging". Other than a proof of concept that it might work, there is nothing here.
- acdha 3y agoCancer is a pretty major health concern for most people and the idea of this general treatment is interesting even if it’s understood to be a very hard problem. HN also has a lot of people who have worked in or adjacent to scientific research so I think there’s always an appreciative upvote for something which starts to look like positive results from something generations of scientists have worked towards.
- elromulous 3y ago+1 Also something showing positive results in humans. So many things have been cured in mice, but don't translate.
- pie420 3y agoAny major examples? I've heard a lot about animal trials succeeding and then the human trials failing, but would love to read into it if you have any sources.
- refurb 3y agoBut what makes this unique versus the hundreds of other early studies that show "encouraging results"? The technique of CAR-T isn't exactly groundbreaking any more with 3 products already on the market. And the ORR of 59% is kinda of in line with current CAR-Ts. I'm going to ESMO and this would be interesting but certainly not the highlight of the data releases. Don't get me wrong, this may turn out to be very exciting, but it's very early data, and similar to other development programs has a 90% chance of failing.
- f6v 3y agoCAR T hasn’t achieved much success in solid tumors yet. Making it work for non-blood cancers would be truly a major milestone for humanity.
- acdha 3y agoYour initial question was why the link was getting upvotes. I don’t think anyone is claiming it’s a medical revolution but a lot of people have or know someone who has been affected by cancer, and anything which offers hope for the future is going to get attention. I don’t mind that, it’s a pleasant change from yet another JavaScript framework.
- ulfw 3y agoBecause cancer is one of the most common most deadly and least treatable diseases out there. I've lost loved ones / family to cancer. Haven't lost any to Covid e.g. Whatever we can do to treat the various cancers out there, the better it is for humanity. I'd much rather have money flow in this that in the next financial / crypto scam.
- nyagaga 3y agoEmployee in a CAR-T company here. More than proof of concept if they went with such a statement to the press. Also, ongoing Phase 1/2 means that by 5-10 years this therapy may become commercial, the initial target being refractory/relapsing tumours as stated in the announcement. It may take some time for the therapeutic target population to be expanded, but this is not a minimal achievement. My view is that this being an autologous therapy (the patient's very own leucocytes are being engineered: the entire manufacturing cycle [I speculate 30-50 days] is done for just a single patient), this will be very expensive and probably only covered on an insurance basis in certain countries only. Still better than nothing, and even science has to make money. The real breakthrough will be arriving to heterologous therapies, where healthy donors leucocytes can be engineered and administered to any patient.
- konschubert 3y agoIn the next five years, how many people will die of a cancer that this could have prevented? Why do we accept this, and aren’t willing to bring it to market faster?
- itishappy 3y agoLiability. This is a perverse incentive structure, but it's not an easy problem. If people die due to your inaction, you are not liable. If people die due to your actions, you very much are. Even a minor issue can end up being harmful. If you have a cancer treatment that's safe and effective, but you haven't fully vetted it and it turns out to be less effective than another available option, then your drug would cause harm. It's safer to test these things, otherwise you get sued, go to jail, your company folds, and nobody gets cancer treatments anymore.
- mschuster91 3y agoI think it should be allowed that, for people with illnesses that end up inevitably fatal in a high percent range, they be allowed to get early access to experimental medication once it's passed some sort of verification. Right now, only those very rich have that chance, they pay the pharma companies (and a host of outright quacks)... I'd love to see cancer medication being accessible for everyone, no matter the amount of money on their bank account.
- omarhaneef 3y agoI think the exciting part is this: “BNT211 continues to show encouraging antitumor activity in patients with CLDN6-positive relapsed or refractory advanced solid tumors” <- interesting because they finally demo some effect in solid tumors in humans “Follow-up of efficacy data at 1x108 CAR-T cells with or without CARVac shows an overall response rate (“ORR”) of 59% and a disease control rate (“DCR”) of 95%, with the CARVac cohort demonstrating a prolonged persistence of CAR-T cells” <- interesting because those are high response rate. Let’s hope it lasts and they can increase those rates but as a patient, you would take this.
- jjtheblunt 3y agoIt’s interesting to HN because BioNTech uses techniques to update a running (biological) system with analogues of patch files, temporarily lived cellular rootkits, etc.
- jjtheblunt 3y agoIt makes me wonder, what will the analogue of a REPL look like in a biological system, and how will it be realized? reason i thought to ask that: https://news.ycombinator.com/item?id=37996164 https://news.ycombinator.com/item?id=37996164
- globalise83 3y agoThe huge accrued warchest from their Covid-19 vaccine plus the proven creativity and technical expertise of their team makes BioNTech an interesting long-term bet.
- stingraycharles 3y agoI’m under the impression that most of these companies started to become heavily overpriced during the COVID-19 period.
- ceejayoz 3y agoLook at the five-year charts for Moderna and BioNTech and it's pretty clear they've gone back to a more normal valuation.
- schleck8 3y agoBiontech has a really impressive pipeline and a good connections globally, look up their pipeline on the website
- Teever 3y agoIf their herpes vaccine works and is also a viable treatment for existing herpes infections they are basically going to have a license to print money.
- schleck8 3y agoCertainly. Let's hope the hedge fund morons don't insider trade like they did with bapi for alzheimer's
- pkaye 3y agoModerna has a good pipeline too: https://www.modernatx.com/research/product-pipeline https://www.modernatx.com/research/product-pipeline As a kidney transplant patient, I'm particularly interested in the latent virus vaccines like CMV, and EBV vaccines. Those who have an organ transplant have to deal recurrence of CMV, EBV and BK virus because they are quite common and latent in the body from past occurrences. I don't know if these vaccine will work on me anymore since I'm already immunosuppressed but there is hope. I'm dealing with both BKV and CMV right now. Treatment is mostly to cut back on immunosuppressants to let your immune systems fight back but that has its own risks. And I never had CMV before while so I'm dealing with those from my donor organ. There are some companies doing trials on antibody treatments right now.
- KaiserPro 3y agothe grade 3/4 cytokine release syndrome is a bit of a worry. But then how different is it from normal cancer treatment?
- f6v 3y agoOne difference would be that you can stop any treatment in case of adverse events. But you can’t remove CAR T cells from the body once they’re in.
- KaiserPro 3y agoI mean yeah, its about balancing risks. I'm guessing that a ~2% chance of a cascade would mean that its not likley to be given as a first like of defence.
- bluGill 3y agoIn a lot of cases we don't have other first line options. it may be no treatment die in 6 months, standard treatment die in 10 months, or this where 2% die in 1 month but 98% are cancer free 1 year later. All numbers above made up, but those are often what we are dealing with. Of course where we have other cancer treatments that works well those should be a first line (at least for now - who knows how this will advance), but all too often we don't have good options.
- qclibre22 3y ago> you can’t remove CAR T cells Well there working on blood purification in severe cases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245117/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245117/ "Four-day extracorporeal blood purification resulted in complete resolution of immune effector cell-associated neurotoxicity syndrome and greater than 95% reduction in interleukin-6 levels without side effects"
- lawlessone 3y agoIf i'm dying of cancer i'd take the risk. Hopefully though they'll have that figured out.
- poszlem 3y agoWe are talking about incurable (refractory) cancer cases in which, after treatment, 95% saw either stabilisation or regression of the disease, and 59% showed significant regression or reduction. This is absolutely awesome news.
- ls612 3y agoNote that this trial is an early trial primarily designed to investigate safety of the treatment. It’s absolutely good news but they need to do a stage 3 trial with a much larger N to convincingly show that it has such a large effect.
- pie420 3y agoAs someone who isn't very familiar with how the clinical phase process works, is it fair to say that before Phase 3 clinical trials, companies can cherry pick patients that look like they will respond well to the treatment? and then Phase 3 is more general?
- jpdus 3y agoFor P1 (which is only to prove safety) this may be the case, but for pivotal studies in P2 and later, participants are almost always randomized so cherry picking shouldn't be possible. But sure, the study design and primary/secondary endpoints are always levers to increase likelihood of admission. There are often long discussions with the FDA and other regulators on how the endpoints and study population should look like.
- database_lost 3y agoCan someone more knowledgeable on the subject please clarify if this proposed therapy requires personalization for each patient or if it can be (eventually) mass produced? Thanks!
- f6v 3y agoAllogenic CAR T seem to be a thing, but graft vs host hasn’t been figured out yet.
- chromatin 3y agoThere is ongoing work in the field of "off the shelf" engineered cell therapy. Current strategies include: - banks of products with major HLA types, so that some matching is still required, but you don't need a 1:1 donor as with bone marrow transplant - stripping, downregulation, or ablation of proteins that coudl cause rejection (eg HLA class II) - expression of other tolerance signals Here is a brief editorial on a paper using some of these stratgies: https://www.nature.com/articles/s41422-022-00745-4 https://www.nature.com/articles/s41422-022-00745-4 Here is a more comprehensive review article: https://ehoonline.biomedcentral.com/articles/10.1186/s40164-023-00435-w https://ehoonline.biomedcentral.com/articles/10.1186/s40164-...
- jessriedel 3y agoThank you for the very thoughtful comment.
- jfarlow 3y agoThere are two kinds of personalization in a [CAR] [T] therapy: 1) using the patient's own cells [personalization of T Cells] 2) customized therapeutic genetic payload, per patient [personalization of the CAR] There are current competing factions for #1 - where cells are from just the patient ["Autologous"] (safer, slower, more expensive), and where the cells are from a universal donor ["Allogeneic"] (possible immune response, but can be manufactured at scale). The therapeutic payload is a DNA sequence encoding a synthetic chimeric receptor ["CAR"]. This sequence is customized based on the details of the patient's particular cancer, but are common across many people. If the cancer has an excess of "Protein X" on it, then the CAR sequence is designed to target Protein X. All patients with a similar cancer profile receive the same CAR sequence as a payload to the T cells. This too could be personalized, to not just profile the _class_ of cancer, but particular to that _specific patent's cancer's profile_ - but this is not yet feasible given the turnaround time to build, test and evaluate a new genetic payload in the context of a person's specific tumor cells. This particular therapy has the cells be from the patient (personalized), but the CAR sequence provided to the cells is common for all people that have the same cancer profile (semi-personalized). In this case, the cancer profile includes those that have an abundance of the protein called Claudin-6.
- trollied 3y agoFor those in the UK, the BBC did a documentary about a trial involving this therapy: https://www.bbc.co.uk/programmes/m0006nzt https://www.bbc.co.uk/programmes/m0006nzt Very interesting.
- victor106 3y agohttps://vimeo.com/347541240 https://vimeo.com/347541240
- jcfrei 3y agoVery encouraging progress. Will be interesting to see whether the anti-covid vaccine crowd will keep the same resentments against cancer vaccines.
- throwaway-blaze 3y agoI think they will come to the conclusion that the benefits of the therapy outweigh the possible risks in this case, in a way they did not for the covid vax.
- Teever 3y agoSome of them will. Some of them will not. https://theprovince.com/news/sheila-annette-lewis-alberta-covid-organ-transplant/wcm/094d3161-34d2-41cb-b2ca-edd2f5a0ca44 https://theprovince.com/news/sheila-annette-lewis-alberta-co...
- Netcob 3y agoThere's a significant amount of people who take the same approach to cancer as they do to diseases such as covid, such as: * Pray * Fast * Take some essential oils / sugar pills * Eat way too much vitamin C * Protest against nearby 5G towers * Take a lot of niacin and figure out what you did wrong in this or a past life while going on a former cruise ship that is filled with asbestos
- doener 3y agoFasting actually could help: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530862/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530862/
- theultdev 3y agoIs that "significant amount of people" based on something or just your own prejudices? Personally most people I know who don't want the covid vax reached that conclusion after weighing the risk/benefit. I'm also from an area where "Pray" would be a significant part of their life, but has nothing to do with their decision.
- tiahura 3y agoOnce again I want to profusely thank the HN'er who posted the story about BioNTech and their herpes vaccine in pre-Wuhan Flu October 19. At the time of that story, one could invest in its ipo @ $13.
- mancerayder 3y agoThere are no near-term catalysts for this one anymore.
- amluto 3y agoIf I understand correctly, this is an infusion of cells that are engineered to kill cells with a certain antigen on their surface along with an injection that makes some non-cancerous cells express that antigen on their surface. Wouldn’t that result in killing a lot of those cells?
- freeone3000 3y agoYes. This makes it significantly better than most existing cancer treatments, which simply kill all dividing cells, thereby killing cancer faster since it divides faster. (Specific cancers have better treatments, but those treatments are one-per-very-specific-cancer and sometimes -per-cancer-per-person, which is very expensive and limited and not available for all cancers.) This treatment targets a type of cancer that is very hard to treat otherwise, and can actually treat several types of cancer!
- v8xi 3y agoIt's important that the CARVac (mRNA vaccine) part of the treatment targets specifically (though how specific, I dont know) dendritic cells which are "professional" antigen-presenting cells in the immune system. During an immune response, dendritic cells gobble up antigens and present them on their surface to help train the immune system so it's more trying to hijack that (very important) part of the immune response rather than training the immune system (and resulting in the death of the "infected" cells) in the way we're used to understanding mRNA vaccines.
- PunchTornado 3y agoTo create the antigen do we need to sequence every individual that received treatment? Is it a personal antigen for everybody?
- Almondsetat 3y agoI think human existence is uniquely tragic in the sense that we can see the cancer right there in the CT scan and yet we can’t do anything about it. We can’t point a finger at the blob and tell our brain to get its shit together and ignore the cancer’s mimetic countermeasures. We first have to completely understand how cancer and our body works and then invent magical chemicals to force our body to intervene like we rationally know it should
- swatcoder 3y agoNah, the unique tragedy is that some humans want to live forever in a mushy world where everything complicated will eventually crumble and rot. Cancer has been right there for millions of years and the pretty slick biological "intervention" was to just continually be spinning up new generations with a clean slate of cells. It seems to work great on the level of humanity as a whole, and countless tools have been offered to help individuals wrap their head around their individual material mortality. No understanding of cancer or bodies required; no magical chemicals needed; no violated "shoulds" involved. That you may now stare at a cancer and panic isn't a universal part of "human existence", it's just a struggle that some individuals see themselves trapped in when they've lost sight of the bigger picture. That's not to say that medical inventions aren't cool, or that they shouldn't be enjoyed, but the starkness of what they're set against is a very personal and subjective thing. What's tragic is that so many people seem cursed to stare at that darkness these days and lack insight into there even being some very robust alternatives to doing so.
- d0odk 3y agoThere are children who die of cancer...
- swatcoder 3y agoYup, and maybe this'll be a help to some. My comment is not pushing back against medical technology, it's pushing back against the idea that human existence is somehow damned to be bleak until some fantastical medical utopia arrives and delivers immortality. You can both enjoy life-extending technology and acknowledge the inevitability of death without all that fretting and drama; many do.
- evantbyrne 3y agoSomewhat related: I wonder how much next-generation biotech is essentially complete, but waiting in regulatory queues? As a layperson, it certainly felt like we got mRNA COVID-19 vaccines _shockingly_ quickly after governments decided they were a priority. The BioNTech website shows 36 technologies in their pipeline that have passed the "preclinical phase".
- ibe3 3y ago[dead]
- markus92 3y agoTrials take by far the longest time in drug development. During COVID, those went rather quickly not only due to accelerated bureaucracy and practically unlimited funding but also the sheer volume of COVID patients speeding inclusion and event rates up way beyond rates normally seen. Getting enough patients enrolled is easy if you have six figure daily infection rates.